The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

20 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

Article Title
RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.EBI
Aventis Pharma
Non-kinase targets of protein kinase inhibitors.EBI
The University Of Sydney
Synthesis and biological activity of pyridopyridazin-6-one p38a MAP kinase inhibitors. Part 2.EBI
Merck Research Laboratories
Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.EBI
Eli Lilly
SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.EBI
Novartis Institutes For Biomedical Research
Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.EBI
Merck Research Laboratories
Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.EBI
Novartis Institutes For Biomedical Research
Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.EBI
Novartis Institutes For Biomedical Research
A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors.EBI
Novartis Institute For Biomedical Research
Imidazopyrimidines, potent inhibitors of p38 MAP kinase.EBI
Johnson & Johnson Pharmaceutical Research And Development
Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.EBI
Merck Research Laboratories
SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.EBI
Novartis Pharma
Mining the PDB for Tractable Cases Where X-ray Crystallography Combined with Fragment Screens Can Be Used to Systematically Design Protein-Protein Inhibitors: Two Test Cases Illustrated by IL1?-IL1R and p38?-TAB1 Complexes.EBI
King'S College London
SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.EBI
Novartis Pharma